Abbott Laboratories recently reported positive Q1 2025 results, showing increased sales and net income, which may have bolstered its share price by 14% last quarter. The enhanced financial performance, including a rise in diluted EPS, highlighted profitability improvements. This, coupled with ongoing stock buybacks and a longstanding commitment to dividends, likely contributed to investor confidence. Despite broader market concerns such as U.S.-China trade tensions impacting tech sectors, Abbott's advancements in product trials and collaborative efforts appear to have positively influenced its performance, in line with market trends indicating a moderate increase over the same period.

You should learn about the 1 warning sign we've spotted with Abbott Laboratories.

The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

The recent positive Q1 2025 results for Abbott Laboratories, with increased sales and net income, align with its ongoing innovation focus in high-growth markets. These developments could strengthen the narrative of sustained growth, even amid potential challenges such as currency fluctuations and pricing pressures in international markets. Analysts have warned that factors like increased tax rates and competitive pressures might impact future earnings, with forecasts suggesting a decline in earnings to US$8.9 billion by 2028 from today's US$13.4 billion. This information offers essential context for understanding the company's financial trajectory.

Over the past five years, Abbott's total shareholder return, including share price appreciation and dividends, was 46.64%. This return demonstrates solid performance compared to the broader US Medical Equipment industry, which saw a more modest 1.9% increase over the past year. However, Abbott's earnings growth in the past year, a very large 134.2%, significantly exceeded the industry average of 18%, illustrating the company's ability to outpace its peers over shorter periods.

The share price increase of 14% last quarter shows investor confidence, supported by favorable Q1 results and future product trials. Despite this uptick, Abbott's current share price of US$123.95 remains below the analyst consensus price target of US$136.47, indicating a potential undervaluation of 9.2%. This gap suggests that there might be room for the stock to grow further if the anticipated revenue and earnings forecasts materialize. In this context, continuing innovation and strategic expansions in leadless pacemakers and glucose monitoring could significantly impact projected financial performance.

In light of our recent valuation report, it seems possible that Abbott Laboratories is trading behind its estimated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:ABT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com